KPTI News 31.09 Karyopharm Therapeutics Inc (KPTI)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Karyopharm Therapeutics Inc (KPTI) 31.09 $KPTI

Karyopharm Announces Initiation of a Phase 1 Study of Decitabine (Dacogen(R)) and Selinexor (KPT-330) in Acute Myeloid Leukemia (AML)
GlobeNewswire - Tue Apr 15, 3:15PM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the initiation of a Phase 1 combination trial of its novel, oral Selective Inhibitor of Nuclear Export (SINE) compound Selinexor (KPT-330) in combination with the DNA methylation inhibitor decitabine (Dacogen) in patients with relapsed or refractory acute myeloid leukemia (AML) and in patients age greater-than or equal to60 years with newly diagnosed AML. The study is being conducted at The Ohio State University Comprehensive Cancer Center under the direction of principal investigator Ramiro Garzon, MD, Associate Professor.

Karyopharm elects Chris Primiano as VP
M2 - Fri Apr 11, 7:31AM CDT
US-based pharmaceutical company Karyopharm Therapeutics (NasdaqGS:KPTI) announced on Thursday that it has hired Christopher B. Primiano as its vice president, general counsel and secretary.

Karyopharm Appoints Chris Primiano as General Counsel
GlobeNewswire - Thu Apr 10, 3:35PM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the appointment of Christopher B. Primiano as Vice President, General Counsel and Secretary.

Karyopharm Therapeutics signs preferred provider agreement with Clinipace Worldwide
M2 - Thu Apr 10, 5:19AM CDT
Pharmaceutical company Karyopharm Therapeutics (NasdaqGS:KPTI) revealed on Wednesday the execution of a preferred provider agreement to manage several clinical programmes, including oncology, wound healing and other diseases in partnership with Clinipace Worldwide .

Karyopharm Therapeutics Inc. Enters into Preferred Provider Agreement with Clinipace Worldwide
Business Wire - Wed Apr 09, 9:00AM CDT
Clinipace Worldwide, a global digital clinical research organization (dCRO), announced today that Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, has entered into a preferred provider agreement with Clinipace to manage several clinical programs, including oncology, wound healing, and other diseases.

Karyopharm Therapeutics to Present at 13th Annual Needham Healthcare Conference
GlobeNewswire - Tue Apr 08, 12:26PM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, announced today that Michael Kauffman, Chief Executive Officer, is scheduled to present a company overview at the 13 Annual Needham Healthcare Conference. The conference is being held at The Westin Grand Central Hotel in New York City. The presentation is scheduled for Wednesday, April 9, 2014 at 8:00 am EDT.

Appointments, Financial Reports, and FDA Approvals - Analyst Notes on Hospira, Karyopharm, Revance, Pluristem, and Sunesis
PR Newswire - Tue Mar 11, 8:19AM CDT
Today, Analysts Review released its analysts' notes regarding Hospira Inc. (NYSE: HSP), Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), Revance Therapeutics, Inc. (NASDAQ: RVNC), Pluristem Therapeutics, Inc. (NASDAQ: PSTI), and Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Karyopharm Therapeutics, Inc. (KPTI) Catches Eye: Stock Jumps 13.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 7:44AM CST
Karyopharm Therapeutics, Inc. was a big mover last session, as the company saw its shares surge 14% on the day

Karyopharm Therapeutics Reports 2013 Year-End Financial Results and Provides Update on Clinical Development Plans
GlobeNewswire - Wed Mar 05, 5:30AM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, reported financial results for the year ended December 31, 2013, and also provided an update on its clinical development plans.

Karyopharm Therapeutics Announces Initiation of an Investigator Sponsored Phase 1 Dose Escalation Study of Its Lead Drug Candidate Selinexor (KPT-330) in Singapore
GlobeNewswire - Thu Feb 27, 8:53AM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the initiation of a Phase 1 study of oral Selinexor in Asian patients with advanced or metastatic solid tumors. Selinexor (KPT-330), is a first-in-class, oral Selective Inhibitors of Nuclear Export (SINE) compound that covalently inhibits exportin-1 (XPO1/CRM1), which leads to the accumulation of tumor suppressor proteins in the cell nucleus and the selective induction of apoptosis in cancer cells. This study is designed to determine the recommended Phase 2 dose and assess the safety and preliminary evidence of anti-cancer activity in Asian patients. The study is being conducted by Drs. David Tan and Goh Boon Cher at the National University Cancer Institute, Singapore (NCIS)/National University Hospital (NUH) in Singapore. Dr. Tan is a consultant medical oncologist at the Department of Haematology-Oncology and Assistant Professor at the Yong Loo Lin School of Medicine, National University of Singapore (NUS). Dr. Goh is Head of the Department of Haematology-Oncology and Deputy Director of the Cancer Science Institute of Singapore at the National University of Singapore.

Karyopharm Therapeutics Announces Nine Presentations on its Selective Inhibitors of Nuclear Export (SINE) Compounds and PAK4 Inhibitors at the American Association of Cancer Research (AACR) Meeting
GlobeNewswire - Wed Feb 26, 3:09PM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the presentation of seven posters covering its Selective Inhibitors of Nuclear Export (SINE) compounds and two posters covering its PAK4 inhibitors at the American Association of Cancer Research (AACR) meeting being held April 5-9, 2014 in San Diego, CA. Karyopharm's lead drug candidate, Selinexor (KPT-330), is a first-in-class, oral SINE compound that is undergoing Phase 1 studies in patients with advanced hematologic malignancies, solid tumors, and sarcomas. Karyopharm's allosteric PAK4 inhibitors are in preclinical development.

BioCryst Pharmaceuticals (BCRX) Jumps: Stock Rises 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 8:39AM CST
BioCryst Pharmaceuticals, Inc. was a big mover last session, as its shares rose almost 11% on the day.

Karyopharm Therapeutics to Present at Upcoming Healthcare Conferences in February
GlobeNewswire - Thu Feb 06, 7:30AM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, announced today that Michael Kauffman, Chief Executive Officer, is scheduled to present at the following conferences in February:

Karyopharm Therapeutics Inc. [KPTI] to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Wed Feb 05, 9:00AM CST
What:

Will Karyopharm (KPTI) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 04, 5:57AM CST
Will Karyopharm (KPTI) Continue to Surge Higher?

This Week in Biotech: Clinical Success, Plus Wheeling and Dealing
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 25, 11:13AM CST
I don't know about you, but to me, between the J.P. Morgan Healthcare Conference two weeks ago and a flurry of earnings and trial data, it seems like an exceptionally furious start to the year for biotech stocks. This marks our third week in a row...

Why Karyopharm Therapeutics, Inc. Shares Vaulted Higher
Sean Williams, The Motley Fool - Motley Fool - Wed Jan 22, 3:13PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Karyopharm Therapeutics , a clinical-stage...

Karyopharm Therapeutics Presents Clinical Data on Selinexor (KPT-330) in Colorectal Cancer From Ongoing Phase 1 Study and Preclinical Data on Novel PAK4 Inhibitors at American Society of Clinical Oncology 2014 Gastrointestinal Cancers Symposium
GlobeNewswire - Wed Jan 22, 7:30AM CST
- Data Demonstrate Preliminary Evidence of Anti-Tumor Activity of Oral Selinexor in Colorectal Cancer Patients -

Karyopharm Therapeutics Announces Data Presentations at American Society of Clinical Oncology Annual Gastrointestinal Cancers Symposium
GlobeNewswire - Tue Jan 14, 7:30AM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the presentation of two posters at the American Society of Clinical Oncology (ASCO) 2014 Gastrointestinal (GI) Cancers Symposium being held January 16-18, 2014 in San Francisco, CA. The posters focus on the potential in GI cancers of lead candidate Selinexor (KPT-330) as well as novel PAK4 inhibitors.

Karyopharm Therapeutics awarded grant from National Multiple Sclerosis Society to further develop SINE compounds
M2 - Thu Jan 09, 4:33AM CST
Karyopharm Therapeutics Inc (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced on Wednesday the award of a grant from the National Multiple Sclerosis (MS) Society through its affiliate, Fast Forward, to support research on the potential of Selective Inhibitors of Nuclear Export (SINE) compounds in inflammatory models of disease, including Multiple Sclerosis (MS).
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 140

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 203

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 71

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 95

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 126

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 78

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 116

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 172

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading

Top 5 Most Recently Viewed Articles

Bitcoin Faces Criticism While BlackRock Sees Financial Success

Updated Category News Views 167

Bitcoin Under Scrutiny In recent discussions, Peter Schiff has taken to social media to share his critical views on Bitcoin, branding it as a "fake asset." His assertion comes after Bitcoin's price retracement from its historic highs, indicating a significant downturn. Currently, Bitcoin is trading at around $81,000 after once peaking at $110,000. Schiff argues that the...

Continue Reading
Valneva Secures $32.8 Million Contract for IXIARO Vaccine Supply

Updated Category News Views 213

Valneva Expands IXIARO Vaccine Supply with New Contract Valneva SE, a leading specialized vaccine company, has officially announced a significant step forward in its partnership with the U.S. Department of Defense (DoD) by signing a new contract valued at a minimum of $32.8 million for the IXIARO vaccine. This substantial agreement marks another chapter in Valneva's...

Continue Reading
EFGH and Minerva Forge Strategic Partnership for Data Centres

Updated Category News Views 118

EFGH and Minerva Unite to Enhance Ghana's Digital Landscape In a landmark agreement, Embed Financial Group Holdings (EFGH) has joined forces with Minerva Data Limited, a prominent player in digital infrastructure, to create advanced data centres and strengthen the technology ecosystem in Ghana. This collaboration marks a significant step in addressing the growing demand...

Continue Reading
Landsea Homes Achieves Remarkable Growth in Q3 Results

Updated Category News Views 50

Strong Financial Performance in Q3 Landsea Homes Corporation (NASDAQ: LSEA) reported impressive financial results for the third quarter, demonstrating robust performance in the residential homebuilding sector. For the quarter, Landsea Homes achieved a net income of $11.1 million, translating to $0.30 per share. This marks a 29% increase in net income compared to the...

Continue Reading
Urban Logistics REIT: Key Disclosure Insights for Investors

Updated Category News Views 219

Understanding the Disclosure from Urban Logistics REIT In the realm of public trading, disclosures play a pivotal role in keeping investors informed about changes in significant stakes within companies. Recently, Urban Logistics REIT Plc, underlining its commitment to transparency, provided valuable insights through its disclosure concerning investor positions, managed by...

Continue Reading